Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000986798 | SCV001135930 | pathogenic | Retinitis pigmentosa 38 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001389819 | SCV001591304 | pathogenic | not provided | 2024-12-24 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 844 of the MERTK protein (p.Arg844Cys). This variant is present in population databases (rs746291728, gnomAD 0.002%). This missense change has been observed in individual(s) with autosomal recessive inherited retinal dystrophy (PMID: 15111602, 28462455). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 801738). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MERTK protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects MERTK function (PMID: 15111602). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV001389819 | SCV002822682 | pathogenic | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | MERTK: PM3:Strong, PM2, PM5, PP4, PS3:Supporting |
Baylor Genetics | RCV000986798 | SCV003835812 | pathogenic | Retinitis pigmentosa 38 | 2022-10-27 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV004818093 | SCV005072556 | pathogenic | Retinal dystrophy | 2023-01-01 | criteria provided, single submitter | clinical testing |